Interleukin-23 (IL-23) Inhibitor Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type
Description
Interleukin-23 (IL-23) Inhibitor Market Summary
Interleukin-23 (IL-23) inhibitors represent a transformative vanguard in autoimmune disease management, precision-blocking the p19 subunit of this pro-inflammatory cytokine to attenuate Th17 pathways without compromising broader immunity, thereby yielding superior remission profiles in psoriasis, psoriatic arthritis, and inflammatory bowel diseases over pan-JAK or TNF antagonists. This market, encompassing monoclonal antibodies and biosimilars like risankizumab, ustekinumab, guselkumab, and emerging mirikizumab, thrives on subcutaneous long-acting regimens that achieve 80-90% PASI-90 responses, alongside expanding labels into ulcerative colitis and Crohn's disease. Hallmarks include reduced injection frequencies—every 12 weeks for some—and favorable safety in long-term extensions, with adverse event rates under 5%, fueling adoption amid a 20% annual rise in autoimmune diagnoses. The sector's maturation integrates biomarker-driven patient selection, such as IL-23 expression assays, with real-world evidence from registries affirming sustained efficacy beyond five years. By 2025, the global IL-23 inhibitor market is poised at 25 to 35 billion USD, projecting a compound annual growth rate (CAGR) of 1.5% to 3.5% through 2030, tempered by biosimilar influxes yet sustained by label broadenings and emerging markets' therapeutic maturation.
● Regional Market Trends
North America anchors the IL-23 inhibitor domain with a CAGR of 1% to 2.5%, led by the United States where payer preferences for high-value biologics and dermatology-rheumatology collaborations propel Skyrizi and Tremfya uptake, with over 1 million patient-years of exposure by 2025 in psoriasis hubs like California clinics. Canada mirrors this via provincial formularies emphasizing cost-offsets from reduced flares. Europe forecasts a CAGR of 1.5% to 3%, with Germany, France, and the UK dominating through NICE and HAS appraisals that prioritize guselkumab for psoriatic arthritis, amid a 10% uptick in biologic initiations despite birth rate declines curbing incidence. Italy and Spain contribute via regional tenders favoring ustekinumab biosimilars for budget constraints. Asia-Pacific anticipates a CAGR of 2.5% to 4%, driven by Japan and China's regulatory harmonization, where Ilumya gains in urban psoriasis centers and Omvoh launches target IBD in high-prevalence zones like South Korea, bolstered by national insurance expansions. India emerges via Sun Pharma's localized manufacturing. Latin America projects a CAGR of 2% to 3.5%, with Brazil and Mexico leading through SUS integrations promoting risankizumab for refractory cases, addressing urban-rural divides in arthritis care. The Middle East and Africa (MEA) region eyes a CAGR of 1.5% to 3%, where Israel and South Africa pioneer Tremfya in academic consortia, yet Gulf states like Saudi Arabia accelerate via Vision 2030 health investments, countering access barriers in North African IBD clusters.
● Application Analysis
Segmented by application, the IL-23 inhibitor market spans psoriasis, psoriatic arthritis, inflammatory bowel diseases, and others, each manifesting tailored characteristics and evolutionary arcs reflective of cytokine redundancy in immune cascades. Psoriasis, the bedrock application comprising 60% of volumes, leverages inhibitors' skin-specific targeting to deliver near-clearance in 70% of moderate-to-severe cases, with trends toward combination therapies with topicals for early intervention, projecting sustained dominance as phototherapy wanes. Psoriatic arthritis evolves with axial involvement endorsements, where guselkumab's enthesitis resolution—up 40% over placebo—heralds a CAGR tilt toward rheumatology, integrating with DMARDs for holistic joint-skin management. Inflammatory bowel diseases, burgeoning at 20% share, spotlight mirikizumab's mucosal healing in ulcerative colitis, with Phase III data showing 50% endoscopic remission, foreshadowing endoscopic biomarkers as predictors and expanding to Crohn's via oral small-molecule hybrids. Others, including hidradenitis suppurativa pipelines, signal diversification, with tildrakizumab's anti-fibrotic potential unlocking niche growth amid 15% annual indication expansions.
● Type Analysis
The type spectrum—risankizumab, ustekinumab, guselkumab, ustekinumab biosimilars, mirikizumab, tildrakizumab, and others—encapsulates potency gradients and accessibility evolutions shaping therapeutic hierarchies. Risankizumab, exemplified by AbbVie's Skyrizi, leads with quarterly dosing and 2024 revenues of 11 to 12 billion USD, its high-affinity binding yielding 85% clear skin in head-to-head trials, trending toward fixed-dose prefilled syringes for adherence. Ustekinumab, via Johnson & Johnson's Stelara at 10 to 11 billion USD in 2024, anchors legacy with biennial efficacy in psoriasis and IBD, yet biosimilars like Samsung Bioepis's Pyzchiva (ustekinumab-ttwe), Amgen's Wezlana (ustekinumab-auub), and Biocon Biologics' Yesintek (ustekinumab-kfce) erode pricing by 40%, catalyzing 25% volume surges in Europe. Guselkumab, Johnson & Johnson's Tremfya generating 3 to 4 billion USD in 2024, differentiates via rapid onset in psoriatic arthritis, with subcutaneous innovations eyeing weekly micro-dosing for flares. Mirikizumab, Eli Lilly's Omvoh (mirikizumab-mrkz) approved in the U.S. and EU in 2025, pioneers IBD frontiers with 60% CDAI remission, poised for subcutaneous-to-IV switches. Tildrakizumab, Sun Pharma's Ilumya/Ilumetri (tildrakizumab-asmn), carves Asian dermatology niches with biennial profiles, while others encompass pipeline IL-23p19 nanobodies, forecasting 5% CAGR as selectivity trumps breadth.
● Company Profiles
Formative entities in the IL-23 inhibitor sphere orchestrate a blend of originator innovation and biosimilar agility, commanding a duopoly tempered by entrants. AbbVie, via Skyrizi (risankizumab), harnesses 11 to 12 billion USD in 2024 sales, leveraging immunology synergies with Humira transitions and global Phase IV networks affirming durability in 500,000 patients. Johnson & Johnson dominates with Stelara (ustekinumab) at 10 to 11 billion USD and Tremfya (guselkumab) at 3 to 4 billion USD in 2024, its Janssen arm excelling in cross-indication trials that extend to ankylosing spondylitis, backed by 2 billion USD R&D allocations. Eli Lilly advances with Omvoh (mirikizumab-mrkz), its 2025 approvals catalyzing IBD pivots and pipeline integrations with JAK inhibitors. Sun Pharma's Ilumya/Ilumetri (tildrakizumab-asmn) fortifies Asian footprints, with localized trials yielding 20% market penetration in India via affordability models. Biosimilar vanguard Samsung Bioepis, with Pyzchiva, Amgen via Wezlana, and Biocon Biologics through Yesintek, collectively target 30% erosion of ustekinumab premiums by 2027, employing equivalence studies across 1,000 subjects to secure tenders in emerging economies. These players navigate patent expiries—Stelara's in 2025—with over 1 billion USD in annual immunology investments, fostering a competitive ethos where data superiority and access strategies delineate leaders.
● Industry Value Chain Analysis
The IL-23 inhibitor value chain delineates a biologics-centric continuum from recombinant engineering to precision delivery, upstream commencing with CHO cell line optimizations for p19-specific monoclonals, sourcing media and vectors from biotech suppliers in Singapore and the U.S., where expression yields of 5-7 g/L dictate scalability amid 10% annual cost declines from perfusion cultures. Midstream purification employs affinity chromatography and viral inactivation, achieving 99.9% purity under GLP, with fill-finish in cold-chain suites ensuring stability for 24-month shelf lives, though aggregate formation risks necessitate advanced analytics like SEC-HPLC. Regulatory nexuses, including EMA's biosimilar pathways, interlace with post-approval commitments for immunogenicity surveillance, adding 15-20% to timelines. Downstream orchestration via specialty pharmacies and infusion centers leverages DTP models in North America, interfacing with PBMs for rebates averaging 40%, while global tenders in Europe optimize volumes exceeding 100,000 units quarterly. Value genesis pivots on outcomes like DLQI improvements of 15 points, justifying list prices of 20,000-30,000 USD annually, yet biosimilars compress to 10,000 USD equivalents, enhancing payer leverage. Terminal links encompass patient support programs with adherence apps tracking 90% compliance, underpinned by HEOR studies quantifying QALY gains of 0.5 per patient-year, fortifying a chain where upstream bioprocessing fuels downstream therapeutic equity in a high-stakes autoimmune paradigm.
● Opportunities and Challenges
The IL-23 inhibitor market, emblematic of biologics' targeted ethos, encounters amplified prospects and headwinds under the Trump administration's tariff edifice, particularly the 100% impost on innovative drugs from October 1, 2025, enforcing U.S. manufacturing quotas for patented biologics to sidestep levies, thereby spurring originators like AbbVie and Johnson & Johnson to amplify domestic fill-finish capacities, potentially harvesting 5-10% margin expansions through exempted logistics and incentivized tax credits under reshoring acts. This paradigm could galvanize biosimilar U.S. launches by Amgen and Samsung Bioepis, streamlining supply for Medicaid-covered psoriasis patients and mitigating 20% of import vulnerabilities, while fostering academic collaborations for next-gen p19 nanobodies tailored to genetic subtypes. In Asia-Pacific, tariff exemptions for API intermediates may invigorate Sun Pharma's indigenization, broadening access in IBD-endemic India via 15% cost reductions. Yet, adversities mount as duties balloon branded import costs—Skyrizi and Tremfya reliant on European sites—by 100%, pressuring list prices and inviting PBM clawbacks that could diminish volumes by 10-15% in commercial segments, widening affordability chasms for uninsured arthritis sufferers. Biosimilar developers like Biocon face revalidation tariffs on reference standards, prolonging market entries by 9-12 months and eroding first-mover edges, while European retaliations fragment pricing corridors, compelling diversified footprints. Qualitatively, the policy ignites manufacturing sovereignty but throttles innovation velocity, compelling entities to fortify hybrid models blending biosimilars with originator extensions and lobby for biologic-specific waivers, traversing a terrain where trade barriers recalibrate the equilibrium of access and advancement.
Interleukin-23 (IL-23) inhibitors represent a transformative vanguard in autoimmune disease management, precision-blocking the p19 subunit of this pro-inflammatory cytokine to attenuate Th17 pathways without compromising broader immunity, thereby yielding superior remission profiles in psoriasis, psoriatic arthritis, and inflammatory bowel diseases over pan-JAK or TNF antagonists. This market, encompassing monoclonal antibodies and biosimilars like risankizumab, ustekinumab, guselkumab, and emerging mirikizumab, thrives on subcutaneous long-acting regimens that achieve 80-90% PASI-90 responses, alongside expanding labels into ulcerative colitis and Crohn's disease. Hallmarks include reduced injection frequencies—every 12 weeks for some—and favorable safety in long-term extensions, with adverse event rates under 5%, fueling adoption amid a 20% annual rise in autoimmune diagnoses. The sector's maturation integrates biomarker-driven patient selection, such as IL-23 expression assays, with real-world evidence from registries affirming sustained efficacy beyond five years. By 2025, the global IL-23 inhibitor market is poised at 25 to 35 billion USD, projecting a compound annual growth rate (CAGR) of 1.5% to 3.5% through 2030, tempered by biosimilar influxes yet sustained by label broadenings and emerging markets' therapeutic maturation.
● Regional Market Trends
North America anchors the IL-23 inhibitor domain with a CAGR of 1% to 2.5%, led by the United States where payer preferences for high-value biologics and dermatology-rheumatology collaborations propel Skyrizi and Tremfya uptake, with over 1 million patient-years of exposure by 2025 in psoriasis hubs like California clinics. Canada mirrors this via provincial formularies emphasizing cost-offsets from reduced flares. Europe forecasts a CAGR of 1.5% to 3%, with Germany, France, and the UK dominating through NICE and HAS appraisals that prioritize guselkumab for psoriatic arthritis, amid a 10% uptick in biologic initiations despite birth rate declines curbing incidence. Italy and Spain contribute via regional tenders favoring ustekinumab biosimilars for budget constraints. Asia-Pacific anticipates a CAGR of 2.5% to 4%, driven by Japan and China's regulatory harmonization, where Ilumya gains in urban psoriasis centers and Omvoh launches target IBD in high-prevalence zones like South Korea, bolstered by national insurance expansions. India emerges via Sun Pharma's localized manufacturing. Latin America projects a CAGR of 2% to 3.5%, with Brazil and Mexico leading through SUS integrations promoting risankizumab for refractory cases, addressing urban-rural divides in arthritis care. The Middle East and Africa (MEA) region eyes a CAGR of 1.5% to 3%, where Israel and South Africa pioneer Tremfya in academic consortia, yet Gulf states like Saudi Arabia accelerate via Vision 2030 health investments, countering access barriers in North African IBD clusters.
● Application Analysis
Segmented by application, the IL-23 inhibitor market spans psoriasis, psoriatic arthritis, inflammatory bowel diseases, and others, each manifesting tailored characteristics and evolutionary arcs reflective of cytokine redundancy in immune cascades. Psoriasis, the bedrock application comprising 60% of volumes, leverages inhibitors' skin-specific targeting to deliver near-clearance in 70% of moderate-to-severe cases, with trends toward combination therapies with topicals for early intervention, projecting sustained dominance as phototherapy wanes. Psoriatic arthritis evolves with axial involvement endorsements, where guselkumab's enthesitis resolution—up 40% over placebo—heralds a CAGR tilt toward rheumatology, integrating with DMARDs for holistic joint-skin management. Inflammatory bowel diseases, burgeoning at 20% share, spotlight mirikizumab's mucosal healing in ulcerative colitis, with Phase III data showing 50% endoscopic remission, foreshadowing endoscopic biomarkers as predictors and expanding to Crohn's via oral small-molecule hybrids. Others, including hidradenitis suppurativa pipelines, signal diversification, with tildrakizumab's anti-fibrotic potential unlocking niche growth amid 15% annual indication expansions.
● Type Analysis
The type spectrum—risankizumab, ustekinumab, guselkumab, ustekinumab biosimilars, mirikizumab, tildrakizumab, and others—encapsulates potency gradients and accessibility evolutions shaping therapeutic hierarchies. Risankizumab, exemplified by AbbVie's Skyrizi, leads with quarterly dosing and 2024 revenues of 11 to 12 billion USD, its high-affinity binding yielding 85% clear skin in head-to-head trials, trending toward fixed-dose prefilled syringes for adherence. Ustekinumab, via Johnson & Johnson's Stelara at 10 to 11 billion USD in 2024, anchors legacy with biennial efficacy in psoriasis and IBD, yet biosimilars like Samsung Bioepis's Pyzchiva (ustekinumab-ttwe), Amgen's Wezlana (ustekinumab-auub), and Biocon Biologics' Yesintek (ustekinumab-kfce) erode pricing by 40%, catalyzing 25% volume surges in Europe. Guselkumab, Johnson & Johnson's Tremfya generating 3 to 4 billion USD in 2024, differentiates via rapid onset in psoriatic arthritis, with subcutaneous innovations eyeing weekly micro-dosing for flares. Mirikizumab, Eli Lilly's Omvoh (mirikizumab-mrkz) approved in the U.S. and EU in 2025, pioneers IBD frontiers with 60% CDAI remission, poised for subcutaneous-to-IV switches. Tildrakizumab, Sun Pharma's Ilumya/Ilumetri (tildrakizumab-asmn), carves Asian dermatology niches with biennial profiles, while others encompass pipeline IL-23p19 nanobodies, forecasting 5% CAGR as selectivity trumps breadth.
● Company Profiles
Formative entities in the IL-23 inhibitor sphere orchestrate a blend of originator innovation and biosimilar agility, commanding a duopoly tempered by entrants. AbbVie, via Skyrizi (risankizumab), harnesses 11 to 12 billion USD in 2024 sales, leveraging immunology synergies with Humira transitions and global Phase IV networks affirming durability in 500,000 patients. Johnson & Johnson dominates with Stelara (ustekinumab) at 10 to 11 billion USD and Tremfya (guselkumab) at 3 to 4 billion USD in 2024, its Janssen arm excelling in cross-indication trials that extend to ankylosing spondylitis, backed by 2 billion USD R&D allocations. Eli Lilly advances with Omvoh (mirikizumab-mrkz), its 2025 approvals catalyzing IBD pivots and pipeline integrations with JAK inhibitors. Sun Pharma's Ilumya/Ilumetri (tildrakizumab-asmn) fortifies Asian footprints, with localized trials yielding 20% market penetration in India via affordability models. Biosimilar vanguard Samsung Bioepis, with Pyzchiva, Amgen via Wezlana, and Biocon Biologics through Yesintek, collectively target 30% erosion of ustekinumab premiums by 2027, employing equivalence studies across 1,000 subjects to secure tenders in emerging economies. These players navigate patent expiries—Stelara's in 2025—with over 1 billion USD in annual immunology investments, fostering a competitive ethos where data superiority and access strategies delineate leaders.
● Industry Value Chain Analysis
The IL-23 inhibitor value chain delineates a biologics-centric continuum from recombinant engineering to precision delivery, upstream commencing with CHO cell line optimizations for p19-specific monoclonals, sourcing media and vectors from biotech suppliers in Singapore and the U.S., where expression yields of 5-7 g/L dictate scalability amid 10% annual cost declines from perfusion cultures. Midstream purification employs affinity chromatography and viral inactivation, achieving 99.9% purity under GLP, with fill-finish in cold-chain suites ensuring stability for 24-month shelf lives, though aggregate formation risks necessitate advanced analytics like SEC-HPLC. Regulatory nexuses, including EMA's biosimilar pathways, interlace with post-approval commitments for immunogenicity surveillance, adding 15-20% to timelines. Downstream orchestration via specialty pharmacies and infusion centers leverages DTP models in North America, interfacing with PBMs for rebates averaging 40%, while global tenders in Europe optimize volumes exceeding 100,000 units quarterly. Value genesis pivots on outcomes like DLQI improvements of 15 points, justifying list prices of 20,000-30,000 USD annually, yet biosimilars compress to 10,000 USD equivalents, enhancing payer leverage. Terminal links encompass patient support programs with adherence apps tracking 90% compliance, underpinned by HEOR studies quantifying QALY gains of 0.5 per patient-year, fortifying a chain where upstream bioprocessing fuels downstream therapeutic equity in a high-stakes autoimmune paradigm.
● Opportunities and Challenges
The IL-23 inhibitor market, emblematic of biologics' targeted ethos, encounters amplified prospects and headwinds under the Trump administration's tariff edifice, particularly the 100% impost on innovative drugs from October 1, 2025, enforcing U.S. manufacturing quotas for patented biologics to sidestep levies, thereby spurring originators like AbbVie and Johnson & Johnson to amplify domestic fill-finish capacities, potentially harvesting 5-10% margin expansions through exempted logistics and incentivized tax credits under reshoring acts. This paradigm could galvanize biosimilar U.S. launches by Amgen and Samsung Bioepis, streamlining supply for Medicaid-covered psoriasis patients and mitigating 20% of import vulnerabilities, while fostering academic collaborations for next-gen p19 nanobodies tailored to genetic subtypes. In Asia-Pacific, tariff exemptions for API intermediates may invigorate Sun Pharma's indigenization, broadening access in IBD-endemic India via 15% cost reductions. Yet, adversities mount as duties balloon branded import costs—Skyrizi and Tremfya reliant on European sites—by 100%, pressuring list prices and inviting PBM clawbacks that could diminish volumes by 10-15% in commercial segments, widening affordability chasms for uninsured arthritis sufferers. Biosimilar developers like Biocon face revalidation tariffs on reference standards, prolonging market entries by 9-12 months and eroding first-mover edges, while European retaliations fragment pricing corridors, compelling diversified footprints. Qualitatively, the policy ignites manufacturing sovereignty but throttles innovation velocity, compelling entities to fortify hybrid models blending biosimilars with originator extensions and lobby for biologic-specific waivers, traversing a terrain where trade barriers recalibrate the equilibrium of access and advancement.
Table of Contents
89 Pages
- Chapter 1 Executive Summary
- Chapter 2 Abbreviation and Acronyms
- Chapter 3 Preface
- 3.1 Research Scope
- 3.2 Research Sources
- 3.2.1 Data Sources
- 3.2.2 Assumptions
- 3.3 Research Method
- Chapter Four Market Landscape
- 4.1 Market Overview
- 4.2 Classification/Types
- 4.3 Application/End Users
- Chapter 5 Market Trend Analysis
- 5.1 Introduction
- 5.2 Drivers
- 5.3 Restraints
- 5.4 Opportunities
- 5.5 Threats
- Chapter 6 Industry Chain Analysis
- 6.1 Upstream/Suppliers Analysis
- 6.2 Interleukin-23 (IL-23) Inhibitor Analysis
- 6.2.1 Technology Analysis
- 6.2.2 Cost Analysis
- 6.2.3 Market Channel Analysis
- 6.3 Downstream Buyers/End Users
- Chapter 7 Latest Market Dynamics
- 7.1 Latest News
- 7.2 Merger and Acquisition
- 7.3 Planned/Future Project
- 7.4 Policy Dynamics
- Chapter 8 Historical and Forecast Interleukin-23 (IL-23) Inhibitor Market in North America (2020-2030)
- 8.1 Interleukin-23 (IL-23) Inhibitor Market Size
- 8.2 Interleukin-23 (IL-23) Inhibitor Market by End Use
- 8.3 Competition by Players/Suppliers
- 8.4 Interleukin-23 (IL-23) Inhibitor Market Size by Type
- 8.5 Key Countries Analysis
- 8.5.1 United States
- 8.5.2 Canada
- Chapter 9 Historical and Forecast Interleukin-23 (IL-23) Inhibitor Market in South America (2020-2030)
- 9.1 Interleukin-23 (IL-23) Inhibitor Market Size
- 9.2 Interleukin-23 (IL-23) Inhibitor Market by End Use
- 9.3 Competition by Players/Suppliers
- 9.4 Interleukin-23 (IL-23) Inhibitor Market Size by Type
- 9.5 Key Countries Analysis
- Chapter 10 Historical and Forecast Interleukin-23 (IL-23) Inhibitor Market in Asia & Pacific (2020-2030)
- 10.1 Interleukin-23 (IL-23) Inhibitor Market Size
- 10.2 Interleukin-23 (IL-23) Inhibitor Market by End Use
- 10.3 Competition by Players/Suppliers
- 10.4 Interleukin-23 (IL-23) Inhibitor Market Size by Type
- 10.5 Key Countries Analysis
- 10.5.1 China
- 10.5.2 India
- 10.5.3 Japan
- 10.5.4 South Korea
- 10.5.5 Southest Asia
- 10.5.6 Australia
- Chapter 11 Historical and Forecast Interleukin-23 (IL-23) Inhibitor Market in Europe (2020-2030)
- 11.1 Interleukin-23 (IL-23) Inhibitor Market Size
- 11.2 Interleukin-23 (IL-23) Inhibitor Market by End Use
- 11.3 Competition by Players/Suppliers
- 11.4 Interleukin-23 (IL-23) Inhibitor Market Size by Type
- 11.5 Key Countries Analysis
- 11.5.1 Germany
- 11.5.2 France
- 11.5.3 United Kingdom
- 11.5.4 Italy
- 11.5.5 Spain
- 11.5.6 Belgium
- 11.5.7 Netherlands
- 11.5.8 Austria
- 11.5.9 Poland
- 11.5.10 Russia
- Chapter 12 Historical and Forecast Interleukin-23 (IL-23) Inhibitor Market in MEA (2020-2030)
- 12.1 Interleukin-23 (IL-23) Inhibitor Market Size
- 12.2 Interleukin-23 (IL-23) Inhibitor Market by End Use
- 12.3 Competition by Players/Suppliers
- 12.4 Interleukin-23 (IL-23) Inhibitor Market Size by Type
- 12.5 Key Countries Analysis
- Chapter 13 Summary For Global Interleukin-23 (IL-23) Inhibitor Market (2020-2025)
- 13.1 Interleukin-23 (IL-23) Inhibitor Market Size
- 13.2 Interleukin-23 (IL-23) Inhibitor Market by End Use
- 13.3 Competition by Players/Suppliers
- 13.4 Interleukin-23 (IL-23) Inhibitor Market Size by Type
- Chapter 14 Global Interleukin-23 (IL-23) Inhibitor Market Forecast (2025-2030)
- 14.1 Interleukin-23 (IL-23) Inhibitor Market Size Forecast
- 14.2 Interleukin-23 (IL-23) Inhibitor Application Forecast
- 14.3 Competition by Players/Suppliers
- 14.4 Interleukin-23 (IL-23) Inhibitor Type Forecast
- Chapter 15 Analysis of Global Key Vendors
- 15.1 AbbVie
- 15.1.1 Company Profile
- 15.1.2 Main Business and Interleukin-23 (IL-23) Inhibitor Information
- 15.1.3 SWOT Analysis of AbbVie
- 15.1.4 AbbVie Interleukin-23 (IL-23) Inhibitor Revenue, Gross Margin and Market Share (2020-2025)
- 15.2 Johnson & Johnson
- 15.2.1 Company Profile
- 15.2.2 Main Business and Interleukin-23 (IL-23) Inhibitor Information
- 15.2.3 SWOT Analysis of Johnson & Johnson
- 15.2.4 Johnson & Johnson Interleukin-23 (IL-23) Inhibitor Revenue, Gross Margin and Market Share (2020-2025)
- 15.3 Eli Lilly
- 15.3.1 Company Profile
- 15.3.2 Main Business and Interleukin-23 (IL-23) Inhibitor Information
- 15.3.3 SWOT Analysis of Eli Lilly
- 15.3.4 Eli Lilly Interleukin-23 (IL-23) Inhibitor Revenue, Gross Margin and Market Share (2020-2025)
- 15.4 Sun Pharma
- 15.4.1 Company Profile
- 15.4.2 Main Business and Interleukin-23 (IL-23) Inhibitor Information
- 15.4.3 SWOT Analysis of Sun Pharma
- 15.4.4 Sun Pharma Interleukin-23 (IL-23) Inhibitor Revenue, Gross Margin and Market Share (2020-2025)
- 15.5 Samsung Bioepis
- 15.5.1 Company Profile
- 15.5.2 Main Business and Interleukin-23 (IL-23) Inhibitor Information
- 15.5.3 SWOT Analysis of Samsung Bioepis
- 15.5.4 Samsung Bioepis Interleukin-23 (IL-23) Inhibitor Revenue, Gross Margin and Market Share (2020-2025)
- 15.6 Amgen
- 15.6.1 Company Profile
- 15.6.2 Main Business and Interleukin-23 (IL-23) Inhibitor Information
- 15.6.3 SWOT Analysis of Amgen
- 15.6.4 Amgen Interleukin-23 (IL-23) Inhibitor Revenue, Gross Margin and Market Share (2020-2025)
- 15.7 Biocon Biologics
- 15.7.1 Company Profile
- 15.7.2 Main Business and Interleukin-23 (IL-23) Inhibitor Information
- 15.7.3 SWOT Analysis of Biocon Biologics
- 15.7.4 Biocon Biologics Interleukin-23 (IL-23) Inhibitor Revenue, Gross Margin and Market Share (2020-2025)
- Please ask for sample pages for full companies list
- Tables and Figures
- Table Abbreviation and Acronyms
- Table Research Scope of Interleukin-23 (IL-23) Inhibitor Report
- Table Data Sources of Interleukin-23 (IL-23) Inhibitor Report
- Table Major Assumptions of Interleukin-23 (IL-23) Inhibitor Report
- Figure Market Size Estimated Method
- Figure Major Forecasting Factors
- Figure Interleukin-23 (IL-23) Inhibitor Picture
- Table Interleukin-23 (IL-23) Inhibitor Classification
- Table Interleukin-23 (IL-23) Inhibitor Applications
- Table Drivers of Interleukin-23 (IL-23) Inhibitor Market
- Table Restraints of Interleukin-23 (IL-23) Inhibitor Market
- Table Opportunities of Interleukin-23 (IL-23) Inhibitor Market
- Table Threats of Interleukin-23 (IL-23) Inhibitor Market
- Table COVID-19 Impact for Interleukin-23 (IL-23) Inhibitor Market
- Table Raw Materials Suppliers
- Table Different Production Methods of Interleukin-23 (IL-23) Inhibitor
- Table Cost Structure Analysis of Interleukin-23 (IL-23) Inhibitor
- Table Key End Users
- Table Latest News of Interleukin-23 (IL-23) Inhibitor Market
- Table Merger and Acquisition
- Table Planned/Future Project of Interleukin-23 (IL-23) Inhibitor Market
- Table Policy of Interleukin-23 (IL-23) Inhibitor Market
- Table 2020-2030 North America Interleukin-23 (IL-23) Inhibitor Market Size
- Figure 2020-2030 North America Interleukin-23 (IL-23) Inhibitor Market Size and CAGR
- Table 2020-2030 North America Interleukin-23 (IL-23) Inhibitor Market Size by Application
- Table 2020-2025 North America Interleukin-23 (IL-23) Inhibitor Key Players Revenue
- Table 2020-2025 North America Interleukin-23 (IL-23) Inhibitor Key Players Market Share
- Table 2020-2030 North America Interleukin-23 (IL-23) Inhibitor Market Size by Type
- Table 2020-2030 United States Interleukin-23 (IL-23) Inhibitor Market Size
- Table 2020-2030 Canada Interleukin-23 (IL-23) Inhibitor Market Size
- Table 2020-2030 South America Interleukin-23 (IL-23) Inhibitor Market Size
- Figure 2020-2030 South America Interleukin-23 (IL-23) Inhibitor Market Size and CAGR
- Table 2020-2030 South America Interleukin-23 (IL-23) Inhibitor Market Size by Application
- Table 2020-2025 South America Interleukin-23 (IL-23) Inhibitor Key Players Revenue
- Table 2020-2025 South America Interleukin-23 (IL-23) Inhibitor Key Players Market Share
- Table 2020-2030 South America Interleukin-23 (IL-23) Inhibitor Market Size by Type
- Table 2020-2030 Asia & Pacific Interleukin-23 (IL-23) Inhibitor Market Size
- Figure 2020-2030 Asia & Pacific Interleukin-23 (IL-23) Inhibitor Market Size and CAGR
- Table 2020-2030 Asia & Pacific Interleukin-23 (IL-23) Inhibitor Market Size by Application
- Table 2020-2025 Asia & Pacific Interleukin-23 (IL-23) Inhibitor Key Players Revenue
- Table 2020-2025 Asia & Pacific Interleukin-23 (IL-23) Inhibitor Key Players Market Share
- Table 2020-2030 Asia & Pacific Interleukin-23 (IL-23) Inhibitor Market Size by Type
- Table 2020-2030 China Interleukin-23 (IL-23) Inhibitor Market Size
- Table 2020-2030 India Interleukin-23 (IL-23) Inhibitor Market Size
- Table 2020-2030 Japan Interleukin-23 (IL-23) Inhibitor Market Size
- Table 2020-2030 South Korea Interleukin-23 (IL-23) Inhibitor Market Size
- Table 2020-2030 Southeast Asia Interleukin-23 (IL-23) Inhibitor Market Size
- Table 2020-2030 Australia Interleukin-23 (IL-23) Inhibitor Market Size
- Table 2020-2030 Europe Interleukin-23 (IL-23) Inhibitor Market Size
- Figure 2020-2030 Europe Interleukin-23 (IL-23) Inhibitor Market Size and CAGR
- Table 2020-2030 Europe Interleukin-23 (IL-23) Inhibitor Market Size by Application
- Table 2020-2025 Europe Interleukin-23 (IL-23) Inhibitor Key Players Revenue
- Table 2020-2025 Europe Interleukin-23 (IL-23) Inhibitor Key Players Market Share
- Table 2020-2030 Europe Interleukin-23 (IL-23) Inhibitor Market Size by Type
- Table 2020-2030 Germany Interleukin-23 (IL-23) Inhibitor Market Size
- Table 2020-2030 France Interleukin-23 (IL-23) Inhibitor Market Size
- Table 2020-2030 United Kingdom Interleukin-23 (IL-23) Inhibitor Market Size
- Table 2020-2030 Italy Interleukin-23 (IL-23) Inhibitor Market Size
- Table 2020-2030 Spain Interleukin-23 (IL-23) Inhibitor Market Size
- Table 2020-2030 Belgium Interleukin-23 (IL-23) Inhibitor Market Size
- Table 2020-2030 Netherlands Interleukin-23 (IL-23) Inhibitor Market Size
- Table 2020-2030 Austria Interleukin-23 (IL-23) Inhibitor Market Size
- Table 2020-2030 Poland Interleukin-23 (IL-23) Inhibitor Market Size
- Table 2020-2030 Russia Interleukin-23 (IL-23) Inhibitor Market Size
- Table 2020-2030 MEA Interleukin-23 (IL-23) Inhibitor Market Size
- Figure 2020-2030 MEA Interleukin-23 (IL-23) Inhibitor Market Size and CAGR
- Table 2020-2030 MEA Interleukin-23 (IL-23) Inhibitor Market Size by Application
- Table 2020-2025 MEA Interleukin-23 (IL-23) Inhibitor Key Players Revenue
- Table 2020-2025 MEA Interleukin-23 (IL-23) Inhibitor Key Players Market Share
- Table 2020-2030 MEA Interleukin-23 (IL-23) Inhibitor Market Size by Type
- Table 2020-2025 Global Interleukin-23 (IL-23) Inhibitor Market Size by Region
- Table 2020-2025 Global Interleukin-23 (IL-23) Inhibitor Market Size Share by Region
- Table 2020-2025 Global Interleukin-23 (IL-23) Inhibitor Market Size by Application
- Table 2020-2025 Global Interleukin-23 (IL-23) Inhibitor Market Share by Application
- Table 2020-2025 Global Interleukin-23 (IL-23) Inhibitor Key Vendors Revenue
- Figure 2020-2025 Global Interleukin-23 (IL-23) Inhibitor Market Size and Growth Rate
- Table 2020-2025 Global Interleukin-23 (IL-23) Inhibitor Key Vendors Market Share
- Table 2020-2025 Global Interleukin-23 (IL-23) Inhibitor Market Size by Type
- Table 2020-2025 Global Interleukin-23 (IL-23) Inhibitor Market Share by Type
- Table 2025-2030 Global Interleukin-23 (IL-23) Inhibitor Market Size by Region
- Table 2025-2030 Global Interleukin-23 (IL-23) Inhibitor Market Size Share by Region
- Table 2025-2030 Global Interleukin-23 (IL-23) Inhibitor Market Size by Application
- Table 2025-2030 Global Interleukin-23 (IL-23) Inhibitor Market Share by Application
- Table 2025-2030 Global Interleukin-23 (IL-23) Inhibitor Key Vendors Revenue
- Figure 2025-2030 Global Interleukin-23 (IL-23) Inhibitor Market Size and Growth Rate
- Table 2025-2030 Global Interleukin-23 (IL-23) Inhibitor Key Vendors Market Share
- Table 2025-2030 Global Interleukin-23 (IL-23) Inhibitor Market Size by Type
- Table 2025-2030 Interleukin-23 (IL-23) Inhibitor Global Market Share by Type
- Table AbbVie Information
- Table SWOT Analysis of AbbVie
- Table 2020-2025 AbbVie Interleukin-23 (IL-23) Inhibitor Revenue Gross Profit Margin
- Figure 2020-2025 AbbVie Interleukin-23 (IL-23) Inhibitor Revenue and Growth Rate
- Figure 2020-2025 AbbVie Interleukin-23 (IL-23) Inhibitor Market Share
- Table Johnson & Johnson Information
- Table SWOT Analysis of Johnson & Johnson
- Table 2020-2025 Johnson & Johnson Interleukin-23 (IL-23) Inhibitor Revenue Gross Profit Margin
- Figure 2020-2025 Johnson & Johnson Interleukin-23 (IL-23) Inhibitor Revenue and Growth Rate
- Figure 2020-2025 Johnson & Johnson Interleukin-23 (IL-23) Inhibitor Market Share
- Table Eli Lilly Information
- Table SWOT Analysis of Eli Lilly
- Table 2020-2025 Eli Lilly Interleukin-23 (IL-23) Inhibitor Revenue Gross Profit Margin
- Figure 2020-2025 Eli Lilly Interleukin-23 (IL-23) Inhibitor Revenue and Growth Rate
- Figure 2020-2025 Eli Lilly Interleukin-23 (IL-23) Inhibitor Market Share
- Table Sun Pharma Information
- Table SWOT Analysis of Sun Pharma
- Table 2020-2025 Sun Pharma Interleukin-23 (IL-23) Inhibitor Revenue Gross Profit Margin
- Figure 2020-2025 Sun Pharma Interleukin-23 (IL-23) Inhibitor Revenue and Growth Rate
- Figure 2020-2025 Sun Pharma Interleukin-23 (IL-23) Inhibitor Market Share
- Table Samsung Bioepis Information
- Table SWOT Analysis of Samsung Bioepis
- Table 2020-2025 Samsung Bioepis Interleukin-23 (IL-23) Inhibitor Revenue Gross Profit Margin
- Figure 2020-2025 Samsung Bioepis Interleukin-23 (IL-23) Inhibitor Revenue and Growth Rate
- Figure 2020-2025 Samsung Bioepis Interleukin-23 (IL-23) Inhibitor Market Share
- Table Amgen Information
- Table SWOT Analysis of Amgen
- Table 2020-2025 Amgen Interleukin-23 (IL-23) Inhibitor Revenue Gross Profit Margin
- Figure 2020-2025 Amgen Interleukin-23 (IL-23) Inhibitor Revenue and Growth Rate
- Figure 2020-2025 Amgen Interleukin-23 (IL-23) Inhibitor Market Share
- Table Biocon Biologics Information
- Table SWOT Analysis of Biocon Biologics
- Table 2020-2025 Biocon Biologics Interleukin-23 (IL-23) Inhibitor Revenue Gross Profit Margin
- Figure 2020-2025 Biocon Biologics Interleukin-23 (IL-23) Inhibitor Revenue and Growth Rate
- Figure 2020-2025 Biocon Biologics Interleukin-23 (IL-23) Inhibitor Market Share
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
